Exothera is a contract development and manufacturing organization (CDMO) specializing in GMP manufacturing services for viral vectors and RNA therapeutics, utilizing fixed bed and stirred tank bioprocessing technologies. The company addresses the need for efficient and scalable production solutions in the development of vaccines and gene therapies, ensuring high yields and quality from pre-clinical stages to commercial readiness.
Funding
$23.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development of vaccines and gene therapies is often hindered by the lack of efficient and scalable GMP manufacturing services for viral vectors and RNA therapeutics. Traditional bioprocessing methods can struggle to achieve the high yields and quality required for both clinical trials and commercial production.
Solution
Exothera is a contract development and manufacturing organization (CDMO) specializing in GMP manufacturing services for viral vectors and RNA therapeutics and vaccines, offering solutions from pre-clinical stages to commercial readiness. The company leverages fixed bed and stirred tank bioprocessing technologies, including novel manufacturing technologies and bioprocessing expertise, to optimize production. By integrating these solutions, Exothera helps clients navigate process development and scale-up challenges, aiming to streamline the journey from concept to market. Their services are designed to support clients at every stage, from discovery to GMP manufacturing.
Target Audience
Exothera serves pharmaceutical and biotechnology companies involved in the development and manufacturing of viral vector-based therapies, RNA therapeutics, and vaccines.
Features
- GMP manufacturing services for viral vectors and RNA therapeutics and vaccines
- Expertise in fixed bed and stirred tank bioprocessing technologies
- Utilization of iCellis and Scale-X bioreactors for viral vector production
- NtensifyTM technology for nucleic acid production
- Process development and scale-up capabilities
- Support from pre-clinical stages to commercial readiness